Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo.
about
Nuclear translocation of urokinase-type plasminogen activatorPAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growthFibrin turnover in lung inflammation and neoplasia.Survey of the year 2000 commercial optical biosensor literature.Blood-brain barrier permeability and tPA-mediated neurotoxicity.Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in miceAngiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPKInhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.Physiology and pathophysiology of the plasminogen system in the kidney.Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation.Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction.Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils.The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins.
P2860
Q30482426-CA8726AB-6159-4D05-8A0D-0B7B4B9AA20AQ33994910-58EE939D-62BC-4923-8674-6D6C48A7EFE9Q34075485-49F89DF0-C465-4BEC-A4AA-273E914A39E7Q34141236-1DCBA98A-B8D7-4211-80E2-ED4EBE6561E5Q34464911-5C3DC744-4D5B-4CDF-8B6E-84A20F4CB642Q35580943-BB488CD2-A65A-4B3E-86C9-375091768F44Q35684859-382F382F-B916-4A82-81BF-4DF5A36DB7E6Q35746906-0E60C742-76CD-477D-8DD3-827112E515A4Q36948533-12EB88D9-B8A0-40C8-AC98-564FAE95ED1FQ37138982-CAAF952B-5443-4498-8892-7B060B45AC7EQ39401678-E6CF184D-3EBE-40B2-9BD9-F0F4C8661616Q41466753-5D13EAFA-DA3C-46F3-8EE6-BBB2C2903070Q42028534-B02D53B6-F063-48EF-AEA8-035E4519A142Q42407503-52711180-44E5-4E25-9E05-FF0A5565D63AQ43208113-D9AFC707-89A8-4087-8182-3BDB60E5065DQ44097437-89761DF0-E881-47C3-80B4-980EC9205B6EQ44760466-8E124586-5597-4274-9CB6-0EA85D8F35F6Q46610587-73AF3BE2-443D-4AB8-8CF3-54680503B392
P2860
Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Urokinase-derived peptides reg ...... traction in vitro and in vivo.
@en
type
label
Urokinase-derived peptides reg ...... traction in vitro and in vivo.
@en
prefLabel
Urokinase-derived peptides reg ...... traction in vitro and in vivo.
@en
P2093
P356
P1433
P1476
Urokinase-derived peptides reg ...... traction in vitro and in vivo.
@en
P2093
Al-Mehdi AB
Haj-Yehia A
Sachais BS
P304
P356
10.1096/FJ.14.10.1411
P407
P577
2000-07-01T00:00:00Z